Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Maternal Interventions to Reduce Asthma: Targeting Novel Endotypes in Early Life

Project description

Personalised prevention to reduce asthma in children

Understanding asthma mechanisms in children can enable personalised prevention. Preliminary research links undetectable 12-HETE in maternal oxylipins to a specific asthma endotype. Additionally, n-3 LCPUFA supplementation during pregnancy may prevent asthma, but only in mothers with detectable 12-HETE levels. The ERC-funded MIRA project will identify mechanisms behind a new childhood asthma endotype linked to oxylipins and develop tailored prevention strategies. It will measure maternal oxylipin profiles during pregnancy and their effects on infant health. The project will also investigate personalised strategies involving prenatal exposure to n-3 long-chain polyunsaturated fatty acids using wild-type and ALOX15-/- transgenic mice. A key innovation is a dried-blood-spot screening tool for pregnant women to enable early risk stratification.

Objective

Asthma is a common childhood disorder with a heterogeneous presentation, representing multiple disease endotypes with distinct underlying mechanisms. Understanding these mechanisms in early life can enable personalised asthma prevention, addressing a significant unmet medical need, but no asthma/wheeze endotypes have been identified in young children that can be targeted. My preliminary findings from untargeted plasma metabolomics profiling in the COPSAC2010 and VDAART birth cohorts showed that maternal oxylipins, particularly undetectable 12-HETE, are associated with a distinct asthma endotype. Further, preliminary data showed a primary preventive effect of n-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) supplementation in pregnancy only among mothers with detectable 12-HETE levels, highlighting a potential for personalised prevention. The MIRA project aims to uncover the mechanisms behind this novel oxylipin-associated childhood asthma endotype and develop tailored prevention strategies. This involves measuring targeted oxylipin profiles and investigating the determinants of maternal oxylipins during pregnancy and their impacts on infant alveolar macrophages (AMs), airway microbiome, longitudinal metabolome and proteome, and asthma outcomes in COPSAC2010 and VDAART. The project will also explore personalised strategies involving prenatal n-3 LCPUFA exposure. Mechanistic studies using wild-type and ALOX15-/- transgenic mice will evaluate the effects and uncover the mechanism. A key innovation of this project is the development of dry blood spot (DBS) screening tool for pregnant women, enabling early risk stratification and personalised intervention. The project will engage in patenting, technology transfer, intellectual property protection, and prototype validation with industry partners, paving the way for integrating the screening tool into prenatal care to prevent childhood asthma before birth.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

REGION HOVEDSTADEN
Net EU contribution
€ 150 000,00
Address
KONGENS VAENGE 2
3400 Hillerod
Denmark
Region
Danmark Hovedstaden Københavns omegn
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Links
Total cost
No data

Beneficiaries (1)